# Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

> **NCT01803282** · PHASE1 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 236 (actual)

## Conditions studied

- Pancreatic Cancer
- Non-small Cell Lung Cancer
- Esophagogastric Cancer
- Colorectal Cancer
- Breast Cancer

## Interventions

- **DRUG:** Andecaliximab
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** 5-FU
- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01803282
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-29
- **Primary completion:** 2019-04-23
- **Final completion:** 2019-04-23
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01803282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01803282, "Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01803282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*